PF-Atlas › Clinical Trials › NCT06574581
ADSCs Therapy in Patients With CTD-ILD
ADSC01 · Phase 1
Registry ID
NCT06574581
Phase
Phase 1
Status
Recruiting
Drug / intervention
ADSC01
Sponsor
China Medical University Hospital
Start
2024-08-20
Enrollment
16
Locations
1
About this trial
Connective tissue disease (CTD), an autoimmune and inflammatory disease, usually accompanied by lung interstitial/alveolar inflammation and fibrosis (so called interstitial lung disease, ILD). The prevalence and mortality rate of CTD-ILD increase in recent several years. Although the use of corticosteroids and strong immunosuppressants can improve ILD in some patients with CTD, progressive lung fibrosis which needs lung transplantation and results in respiratory failure, even with mortality is observed. Currently, stem cell therapy is a breakthrough in the treatment of CTD-ILD, and the effective therapy with stem cells for patients with ILD have been reported.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT06574581 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.